Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

How to Treat MDS without Stem Cell Transplantation

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Using A3 Methodology to Identify the Root Cause of a Chemotherapy Error in a Hematopoietic Stem Cell Transplant Patient Kathlene DeGregory, PharmD, BCOP,

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Inhaled Cyclosporine For The Treatment Of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) Or Lung Transplantation by.

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA)

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Access to Hematopoietic Cell Transplantation in the United States

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.

Pharmacogenetic Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants Ashley Teusink,

Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis.

Let Them Eat! Comparing a Neutropenic Diet to a Food Safety Based Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Cynthia.

Caroline F. Morrison, Donna M

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Pulmonary Hypertension Associated with Bronchiolitis Obliterans after Stem Cell Transplant Christopher E. Dandoy, MD, MSc, Abigail Pate, Mikako Warren,

Long-Term Outcome of Fludarabine-Based Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Debilitating Paroxysmal Nocturnal Hemoglobinuria

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Bone Mineral Density (BMD) Improves in Survivors in Their Second Decade Post- Allogeneic Stem Cell Transplantation and Is Influenced By Body Mass Index.

Craig J. Galban, PhD, Jennifer L. Boes, PhD, Maria Bule, Charles R

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies Stefan O. Ciurea, Richard.

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Potential Use of Human Placenta Derived Stem Cell (HPDSCs) As a Novel Stem Cell Source for the Treatment of Recessive Dystrophic Epidermolysis Bullosa.

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Identification of Potential Barriers and Incentives for BMT Nurses to Apply for and Maintain BMTCN Certification Brittney Nicole Browne, BSN, RN, OCN,

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation Koji Sasaki, MD, Rima Saliba, PhD, Gary.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Development of an Assessment Tool for Patient Evaluation Prior to Hematopoietic Stem Cell Transplantation (HSCT) Jaskiran Kaur, Madhu Ragupathi, Eric.

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Blood and Marrow Transplant Handbook

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Mammen Chandy Biology of Blood and Marrow Transplantation

Praveena Narayanan, Alexandra Wolanskyj, Shawna L. Ehlers, Mark R

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment Duncan Purtill,

Close Monitoring of Cyclosporine A Concentration as a Means of Preventing Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients Marietta.

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Cerebral Venous Thrombosis after Autologous Stem Cell Transplantation

Presentation transcript:

Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation Enkhtsetseg Purev, MD, Nicole Gormley, MD, Catalina Ramos, BSN, Robert Reger, MS, Xin Tian, PhD, Elena Cho, RN, Debra Reda, RN, Clara Chen, MD, Anthony F. Suffredini, MD, Richard W. Childs, MD Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages S347-S348 (February 2015) DOI: 10.1016/j.bbmt.2014.11.552 Copyright © 2015 Terms and Conditions

Figure 1 FEV1 and prednisone dose for Subject 8A and 14A Biology of Blood and Marrow Transplantation 2015 21, S347-S348DOI: (10.1016/j.bbmt.2014.11.552) Copyright © 2015 Terms and Conditions